APOC3 and familial chylomicronemia syndrome: To date, Volanesorsen is a second generation antisense oligonucleotide that has been designed to target APOC-III mRNA and is currently being evaluated in phase 3 clinical trials in patients with familial chylomicronemia syndrome (The APPROACH Study, The COMPASS Study) (Table 4).